November 04-08, 2022
Washington DC USA

American Association for the Study of Liver Diseases.

Explore more information for Gilead Liver Diseases therapies
Results (7)

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: an integrated safety analysis of 48-week data

Efficacy of Bulevirtide as Monotherapy for Chronic Hepatitis D (CHD): Week-48 Results From an Integrated Analysis

Combination Therapy with Cilofexor and Firsocostat Improves Plasma Fibrosis Biomarkers in Patients with Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis

Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence And Rapid Onset Of HCV RNA Undetectability After 4 Weeks of Treatment with Sofosbuvir/Velpatasvir

No Detected Resistance to Tenofovir Alafenamide (TAF) Treatment in Children and Adolescents with Chronic Hepatitis B (CHB): Results From Week 24 Primary Endpoint Analysis

Bulevirtide improves health related quality life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a phase 3 trial at 48 weeks

Safety and efficacy at 1 year in children and adolescents with chronic hepatitis B (CHB) receiving tenofovir alafenamide (TAF)